Brought to you by 
Genentech licenses Idec B-cell lymphoma treatment
Mar 1995
Executive Summary
Genentech has licensed worldwide rights to Idec's IDEC-C2B8, a CD20-directed monoclonal antibody in Phase III for the treatment of non-Hodgkins B-cell lymphoma, in exchange for a potential $57 million.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R+D and Marketing-Licensing
- Includes Equity
- Intra-Biotech Deal
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech licenses Idec B-cell lymphoma treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice